Switch theme
Sign up to access all valuation multiples
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
1979
53K+
LTM Revenue $17.9B
LTM EBITDA $5.4B
$167B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Boston Scientific has a last 12-month revenue (LTM) of $17.9B and a last 12-month EBITDA of $5.4B.
In the most recent fiscal year, Boston Scientific achieved revenue of $16.7B and an EBITDA of $3.9B.
Boston Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Boston Scientific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.9B | XXX | $16.7B | XXX | XXX | XXX |
| Gross Profit | $12.6B | XXX | $11.5B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $5.4B | XXX | $3.9B | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $4.9B | XXX | $3.0B | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $4.0B | XXX | $1.9B | XXX | XXX | XXX |
| Net Margin | 22% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $10.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Boston Scientific's stock price is $105.
Boston Scientific has current market cap of $156B, and EV of $167B.
See Boston Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167B | $156B | XXX | XXX | XXX | XXX | $2.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Boston Scientific has market cap of $156B and EV of $167B.
Boston Scientific's trades at 10.0x EV/Revenue multiple, and 43.2x EV/EBITDA.
Equity research analysts estimate Boston Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boston Scientific has a P/E ratio of 39.1x.
See valuation multiples for Boston Scientific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $156B | XXX | $156B | XXX | XXX | XXX |
| EV (current) | $167B | XXX | $167B | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | 31.0x | XXX | 43.2x | XXX | XXX | XXX |
| EV/EBIT | 34.1x | XXX | 55.5x | XXX | XXX | XXX |
| EV/Gross Profit | 13.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 39.1x | XXX | 84.0x | XXX | XXX | XXX |
| EV/FCF | 59.2x | XXX | 70.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBoston Scientific's last 12 month revenue growth is 14%
Boston Scientific's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Boston Scientific's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boston Scientific's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Boston Scientific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boston Scientific acquired XXX companies to date.
Last acquisition by Boston Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Boston Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Boston Scientific founded? | Boston Scientific was founded in 1979. |
| Where is Boston Scientific headquartered? | Boston Scientific is headquartered in United States of America. |
| How many employees does Boston Scientific have? | As of today, Boston Scientific has 53K+ employees. |
| Who is the CEO of Boston Scientific? | Boston Scientific's CEO is Mr. Michael F. Mahoney. |
| Is Boston Scientific publicy listed? | Yes, Boston Scientific is a public company listed on NYS. |
| What is the stock symbol of Boston Scientific? | Boston Scientific trades under BSX ticker. |
| When did Boston Scientific go public? | Boston Scientific went public in 1992. |
| Who are competitors of Boston Scientific? | Similar companies to Boston Scientific include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Boston Scientific? | Boston Scientific's current market cap is $156B |
| What is the current revenue of Boston Scientific? | Boston Scientific's last 12 months revenue is $17.9B. |
| What is the current revenue growth of Boston Scientific? | Boston Scientific revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Boston Scientific? | Current revenue multiple of Boston Scientific is 9.3x. |
| Is Boston Scientific profitable? | Yes, Boston Scientific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boston Scientific? | Boston Scientific's last 12 months EBITDA is $5.4B. |
| What is Boston Scientific's EBITDA margin? | Boston Scientific's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Boston Scientific? | Current EBITDA multiple of Boston Scientific is 31.0x. |
| What is the current FCF of Boston Scientific? | Boston Scientific's last 12 months FCF is $2.8B. |
| What is Boston Scientific's FCF margin? | Boston Scientific's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Boston Scientific? | Current FCF multiple of Boston Scientific is 59.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
